Aura Biosciences

Beyond ocular cancers, Aura’s VDC technology has the potential to be applied to an almost limitless list of other types of solid tumors.

Choroidal melanoma is a vision and life-threatening ocular cancer that occurs in approximately 11,000 patients per year worldwide.

Aura Biosciences develops therapies for ocular cancers to improve patient outcomes and seeks marketing approval for treatments.

Ocular cancers are a group of rare, life-threatening conditions that affect the eyes, including choroidal melanoma, uveal melanoma, cancers of the ocular surface and retinoblastoma, among others.

Therapeutic Delivery | Ma, et al.

Retina Specialist

Listen to this podcast to learn more about how Aura CEO Eli de los Pinos built the company from the ground up around viral-like synthetic nanoparticles that are closely related to wild type viruses in structure and behavior but lack any viral DNA.

Virus-like particle-drug conjugates induce protective, long-lasting adaptive anti-tumor immunity in the absence of specifically targeted tumor antigens

Aura Biosciences closed an $80 million financing round led by Matrix Capital Management and Surveyor Capital, with participation from new investors.

Aura Biosciences published data in *Cancer Immunology Research* supporting its virus-like drug conjugate technology platform for cancer treatment.

Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Sapna Srivastava, Ph.D., to its Board of Directors.

Aura Biosciences appointed Mark De Rosch, Ph.D., as Chief Operating Officer to lead global operations and regulatory strategy.

The Ophthalmologist

Aura biosciences is a clinical-stage company developing a novel, virus-like drug conjugate technology platform for the treatment of multiple cancer indications.

Evangelos Gragoudas is a leading clinician-researcher and has spent over 25 years investigating treatments for intraocular tumors and macular disorders.

Jay S. Duker, M.D., directs the New England Eye Center, one of the largest academic ophthalmology practices in the United States, and holds the roles of Professor and Chairman of the Department of Ophthalmology at Tufts Medical Center and Tufts University School of Medicine.

Aura Biosciences pioneers a first-in-class treatment for solid tumors, initially focusing on cancers like choroidal melanoma where patients lack effective options.